Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 2/20 | 0.49 |
| ▸ | CDK9 | P50750 | 2/20 | 0.49 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 9/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1440085 | 0.85 | LRRK2 (0.43) | CCNT1CDK9ALOX5APFEN1JAK2 | |
| SCHEMBL9929435 | 0.82 | CCNT1 (0.52) | CCNT1CDK9ABL1KCNQ3KCNQ2 | |
| SCHEMBL23520406 | 0.77 | CDK9 (0.45) | CCNT1CDK9ALOX5APFEN1 | |
| SCHEMBL30507417 | 0.77 | CDK9 (0.45) | CCNT1CDK9ALOX5APFEN1 | |
| SCHEMBL23520275 | 0.76 | ALOX5AP (0.50) | CCNT1CDK9ALOX5APFEN1JAK2 | |
| SCHEMBL21223516 | 0.74 | MCHR1 (0.46) | CCNT1CDK9ALOX5APFEN1JAK2 | |
| Hydrazine SCHEMBL27484593 | 0.72 | CSNK2A1 (0.57) | CSNK2A1ACLY | |
| SCHEMBL10939237 | 0.71 | CSNK2A1 (0.56) | CSNK2A1ACLY | |
| SCHEMBL1439355 | 0.71 | CCNT1 (0.44) | CCNT1CDK9JAK2JAK3 | |
| SCHEMBL25345535 | 0.70 | ALOX5AP (0.42) | ALOX5APFEN1JAK2MAP4K4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2473502-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2012-07-11 | — | — | EP | claimed |
| EP-2473502-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | PFISTER KEITH B (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | CDK2, CDK1, CDK6 | CCNT1 80/4885CDK9 6/4885ALOX5AP 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.